Literature DB >> 23254404

Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.

F Parente1, C Boemo, A Ardizzoia, M Costa, P Carzaniga, A Ilardo, R Moretti, M Cremaschini, E M Parente, M E Pirola.   

Abstract

BACKGROUND AND STUDY AIMS: Colorectal cancer (CRC) screening aims to reduce mortality by detecting cancers at an early stage and removing adenomatous polyps at an acceptable cost. The aim of the current study were to assess the outcomes and costs of the first two biennial rounds of a population-based CRC screening program using the immunochemical fecal occult blood test (i-FOBT) in a northern Italian province.
METHODS: All residents aged 50 - 69 years were invited to take part in a biennial screening program using a 1-day i-FOBT, followed by colonoscopy in positive individuals. The i-FOBT uptake, compliance to colonoscopy, detection rate for cancer or advanced adenomas according to age and sex, and direct cost analysis were carried out separately for the 1st and 2nd rounds of screening.
RESULTS: In 78 083 (1st round) and 81 619 (2nd round) individuals who were invited to screening, the participation rates were 49.7 % and 54.4 % and i-FOBT positivity rates were 6.2 % and 5.8 %, respectively. Detection rates for cancer and advanced adenomas were lower in the 2nd screening compared with the 1st one (1.6‰ vs. 2.5‰ for cancers and 15.8‰ vs. 17.9‰ for advanced adenomas, respectively), whereas positive predictive values for cancer and advanced adenoma were similar in both rounds. In 165 adenocarcinomas detected, 52 % were Dukes' stage A and 21 % were stage B. All cost indicators were slightly higher in the 1st round of screening compared with the 2nd. The direct cost per cancer or advanced adenoma detection was similar in the two rounds (€ 1252 and € 1260, respectively).
CONCLUSIONS: Compliance and diagnostic yield of i-FOBT screening were satisfactory. Most detected cancers were at a very early stage. Program costs were reasonable and did not increase with repeat screening. Screening could contribute to decreasing the cost of CRC care by improving the stage at diagnosis. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23254404     DOI: 10.1055/s-0032-1325800

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  25 in total

1.  Inadequate Utilization of Diagnostic Colonoscopy Following Abnormal FIT Results in an Integrated Safety-Net System.

Authors:  Rachel B Issaka; Maneesh H Singh; Sachiko M Oshima; Victoria J Laleau; Carly D Rachocki; Ellen H Chen; Lukejohn W Day; Urmimala Sarkar; Ma Somsouk
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

2.  FITting ADR to colonoscopy indication.

Authors:  C Hassan; A Repici; D K Rex
Journal:  United European Gastroenterol J       Date:  2016-09-20       Impact factor: 4.623

3.  Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.

Authors:  Grace Clarke Hillyer; Karen M Schmitt; Daniel E Freedberg; Rachel A Kramer; Yin Su; Richard M Rosenberg; Alfred I Neugut
Journal:  Am J Prev Med       Date:  2014-06-17       Impact factor: 5.043

4.  Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.

Authors:  Vivy T Cusumano; Folasade P May
Journal:  J Gen Intern Med       Date:  2020-03-03       Impact factor: 5.128

5.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

Review 6.  Diagnostic value of interleukin-8 in colorectal cancer: a case-control study and meta-analysis.

Authors:  Wen-Jun Jin; Jin-Ming Xu; Wen-Li Xu; Dong-Hua Gu; Pei-Wei Li
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 7.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

8.  Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Authors:  Christopher D Jensen; Douglas A Corley; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Wei K Zhao; Amy R Marks; Joanne E Schottinger; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Carrie N Klabunde; Charles P Quesenberry; Theodore R Levin; Pauline A Mysliwiec
Journal:  Ann Intern Med       Date:  2016-01-26       Impact factor: 25.391

9.  Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.

Authors:  Amit G Singal; Samir Gupta; Jasmin A Tiro; Celette Sugg Skinner; Katharine McCallister; Joanne M Sanders; Wendy Pechero Bishop; Deepak Agrawal; Christian A Mayorga; Chul Ahn; Adam C Loewen; Noel O Santini; Ethan A Halm
Journal:  Cancer       Date:  2015-11-04       Impact factor: 6.860

10.  Anatomic distribution of cancers and colorectal adenomas according to age and sex and relationship between proximal and distal neoplasms in an i-FOBT-positive average-risk Italian screening cohort.

Authors:  F Parente; S Bargiggia; C Boemo; C Vailati; E Bonoldi; A Ardizzoia; A Ilardo; F Tortorella; S Gallus
Journal:  Int J Colorectal Dis       Date:  2013-08-24       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.